Arla Foods Ingredients launch new Lacprodan CGMP-30 ingredient

In a recent press release, Arla Foods Ingredients announced the launch of a new casein glycomacropeptide (CGMP) ingredient called Lacprodan CGMP-30. The new ingredient consists of lower levels of phenylalanine.

Lacprodan CGMP-30 may be helpful with phenylketonuria (PKU), which is a metabolic disorder that affects an estimated one in 24,000 newborns around the world.^1,2 According to the press release, PKU “impairs the body’s ability to metabolise phenylalanine, an amino acid naturally abundant in dietary proteins. Without management, PKU causes phenylalanine to accumulate in the blood and brain, which can lead to severe intellectual disability, epilepsy and behavioural problems.”¹

A traditional treatment for PKU was having individuals adhere to a low-protein diet and utilize protein substitutes throughout their lives. The press release mentions that individuals may often suffer from gastrointestinal discomfort, and experience issues involving taste and palatability.¹

Arla Foods Ingredients previously launched Lacprodan CGMO-20, a highly purified CGMP containing low levels of phenylalanine. Clinical research on the supplement has shown that partially replacing free amino acids with Lacprodan CGMP-20 in a protein substitute may help with gastrointestinal symptoms.¹

Lacprodan CGMP-30 contains 50% less phenylalanine which may help with patients that are phenylalanine-sensitive.

Mads Dyrvig, Head of Sales Development, Specialised Nutrition, at Arla Foods Ingredients, said, “For many years, Lacprodan^® CGMP-20 has been helping patients with PKU, supporting compliance with their dietary regimens to help improve their quality of life. Our new Lacprodan^® CGMP-30 represents a major advance because it offers even lower phenylalanine content. As such, we anticipate that it will be a unique new solution for blood phenylalanine control, as well as improved gastrointestinal comfort, in the most phenylalanine-sensitive PKU patients. Its taste and palatability are also superior to solutions based on free amino acids, offering further benefits for quality of life.”¹

Brazil Approves Lacprodan MFGM-10

Arla Foods Ingredients announced in a recent press release that their Lacprodan MFGM-10 ingredient has received approval by Brazilian authorities for usage in both food and beverages.³ The ingredient is listed among Arla Foods Ingredients’ product portfolio that includes ingredients consisting of whey protein, complex milk lipids, and other nutrients. According to the press release, MFGM is “best known” for being an infant formula ingredient but also provides support for older children and adults.

The approval decision from Brazil’s Ministry of Agriculture, Livestock, and Food Supply (MAPA), allows for manufacturers to include “Whey protein concentrate enriched with milk fat globule membrane,”.³ Additionally, the approval could lead for other MFGM ingredients to be approved under the same designation, such as Nutrilac MFGM.

Currently, MFGM is not authorized for use in categories that include supplements, follow-on formula, and infant formula. These categories are reviewed by ANVISA, Brazil’s health regulatory agency.³

Camila Oshima, Regulatory Specialist at at Arla Foods Ingredients, said³, “This is a major milestone in our long-term ambition to bring the benefits of our MFGM ingredients to the increasingly important Brazilian market. ​ As well as being a major benefit to manufacturers of conventional food and beverage products containing whey protein, it further demonstrates that MFGM is safe, and is an important first step towards approval in infant formula and other health products.”

MFGM Ingredient Receives EU and Australian Approval

In July 2025, Arla Foods Ingredients announced that their milk fat globule membrane (MFGM) ingredient has been approved in Australia to be used in infant formula products and that the company has obtained exclusive commercialization rights.⁴

In Australia, Arla Foods Ingredients’ Lacprodan MFGM-10 is the company’s first early life nutrition product to receive approval. Additionally, for at least 15 months, it is the only MFGM ingredient to be approved for use in products for infants in Australia.⁴ The ingredient MFGM is found naturally in human milk and consists of gangliosides, phospholipids, and sphingolipids. According to the press release, MFGM-10 is the global formula market’s first bovine MFGM ingredient and has been shown to support immune health and infant nutrition.

The Food Standards Australia New Zealand (FSANZ) approved MFGM to be included as a nutritive substance in infant formula products on April 30, 2025.⁴ The ingredient’s approval is now in effect after receiving formal acceptance by the Australia and New Zealand Food Ministers Meeting. In Australia, Lacprodan MFGM-10 is allowed to be labeled as “Milk fat globule membrane-enriched whey protein concentrate.”⁴ In New Zealand, this is not the case because the country has decided to opt out of the standard used for Australia-New Zealand joint infant formula products. In the EU, Lacprodan MFGM-10 is not considered to be a novel food which allows the product to be utilized in both products for infants and adults.

References

1. New CGMP ingredient has even lower phenylalanine content https://arla-foods-ingredients.prezly.com/new-cgmp-ingredient-has-even-lower-phenylalanine-content (accessed Dec 17, 2025).
2. Hillert, A., et al., The Genetic Landscape and Epidemiology of Phenylketonuria. Am J Hum Genet, 2020. 107(2): p. 234-250
3. Colli, M. Lacprodan MFGM-10 obtains approval in Brazil https://www.nutritionaloutlook.com/view/lacprodan-mfgm-10-obtains-approval-in-brazil (accessed Dec 17, 2025).
4. Colli, M. Arla foods ingredients receives approval for use of MFGM in infant formula https://www.nutritionaloutlook.com/view/arla-foods-ingredients-receives-approval-for-use-of-mfgm-in-infant-formula (accessed Dec 11, 2025).